Auszug
Hauptvertreter der Osteoporosemittel sind Bisphosphonate, die in der Onkologie auch dem Schutz vor Knochenmetastasen dienen. Leitsubstanz der Bisphosphonate ist Alendronsäure, auf die jetzt über 60% des Verordnungsvolumens dieser Stoffgruppe entfallen. Mit weitem Abstand folgen Raloxifen und Fluoridpräparate mit deutlich rückläufiger Tendenz. Kräftig angestiegen ist die Verordnung des 2004 eingeführten Strontiumranelat.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Literatur
American Medical Association (1986): Agents affecting calcium metabolism. In: Drug Evaluations, 6th ed, Saunders Company, Philadelphia, pp. 827–839, 885–902.
Arzneimittelkommission der Deutschen Ärzteschaft (2007): Empfehlungen zur Therapie und Prophylaxe der Osteoporose. Arzneiverordnung in der Praxis (Sonderheft 34S), 2. Auflage. Im Internet: www.akdae.de/35/83_Osteoporose_2007_2Auflage.pdf
Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG (2004): Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516–1525.
Block GA, Raggi P, Bellasi A et al (2007): Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 71: 438–441.
Bone HG, Hosking D, Devogelaer D et al (2004): Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 1189–1199.
Dawson-Hughes B, Harris SS, Krall EA, Dallai GE (1997): Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337: 670–676.
Djavan B, Thompson I, Michel MS, Waldert M, Scitz C (2004): Chemoprävention des Prostatakarzinoms. Urologe A 43: 557–561.
Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK et al for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators (1999): Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282: 637–645.
Fassbender WJ, Stumpf UC, Jockenhövel F (2006): Evidenzbasierte medikamentöse Therapie der Osteoporose. Med Klinik 101 Sondernr. 1: 178–181.
Fleisch H (2000): Bisphosphonates in bone disease. From the laboratory to the patient. 4th ed, Academic Press, San Diego etc., pp. 1–212.
Haguenauer D, Welch V, Shea B, Tugwell P, Wells G (2000): Fluoride for treating postmenopausal osteoporosis. Cochrane Database Syst Rev. 2000;(4): CD002825.
Hersh AL, Stefanick ML, Stafford RS (2004): National use of postmenopausal hormone therapy. Annual trends and response to recent evidence. JAMA 291: 47–53.
Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE et al; Women’s Health Initiative Investigators (2006): Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354: 669–683.
Keaveny TM, Donley DW, Hoffmann PF et al (2007): Effects of teriporatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scars in women with osteoporosis. J Bone Miner Res 21: 149–157.
Manns B, Klarenbach S, Lee H, Culleton B, Shrive F, Tonelli M (2007): Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant. 2007 Jun 25; [Epub ahead of print]
Meunier PJ, Roux C, Seeman E et al (2004): The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350: 459–486.
Mousny M, Bouse X, Wise L et al. (2006): The genetic influence on bone susceptibility to fluoride. Bone 39: 1283–1289.
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY et al (2001): Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434–1441.
NIH Consensus Conference (1994): Optimal calcium intake. JAMA 272: 1942–1948.
Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ (2005): Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of peripheral osteoporosis (TROPOS) Study. J Clin Endocrinol Metab 90: 2816–2822.
Riggs BL, O’Fallon WM, Lane A, Hodgson SF, Wahner HW et al (1994): Clinical trial of fluoride therapy in postmenopausal osteoporotic women: Extended observations and additional analysis. J Bone Miner Res 9: 265–275.
Schousboe JT, Nyman JA, Kane RL, Eusrud KE (2005): Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med 142: 734–741.
Silverberg SJ, Fairman C, Bilezikian JP et al (2004): Cinacalcet HCl effectively treats hypercalcemia in patients with parathyroid carcinoma (abstract no. SA495). J Bone Miner Res 19 Suppl. 1: S103.
Suki W, Zabaneh R, Cangiano J, Reed J, Fischer D, Garrett L, Ling B, Chasan-Taber S, Dillon M, Blair A, Burke S (2006): A prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients. The DCOR trial. Nephrol Dial Transplant 21(Suppl 4): 145–146.
Wüster C, Ziegler R (1993): Fluorid-Therapie der Osteoporose: “Auf die Dosis kommt es an”. Dtsch Ärztebl 90: B–41–42.
Ziegler R (2002): Osteoporose: aktuelle Diagnostik und Therapie. Orthopädische Praxis 38: 570–577.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Schwabe, U., Ziegler, R. (2008). Osteoporosemittel. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2007. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-72548-0_40
Download citation
DOI: https://doi.org/10.1007/978-3-540-72548-0_40
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-72547-3
Online ISBN: 978-3-540-72548-0
eBook Packages: Medicine (German Language)